Clinigen to supply and distribute PAION AG’s key products in UK
Clinigen Group has entered into an exclusive partnership with German specialty pharma company PAION AG for supplying and distributing the latter’s key products into the UK.
According to the UK-based specialist pharmaceutical services and products company, the first product under the agreement will be Byfavo (remimazolam), an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. It was approved in March 2021 by the European Commission (EC) and in the UK by the Medicines & Healthcare products Regulatory Agency (MHRA) in June 2021.
Byfavo is the first product developed by the German specialty pharma company to get approval and launch in Europe.
Katja Lundell — PAION UK General Manager said: “We are delighted to partner with Clinigen for the commercial launch of Byfavo, leveraging their strong regulatory, supply and distribution capabilities to ensure broad access of this important product in the UK. We look forward to working with them on this and our other products.”
Additionally, PAION has GIAPREZA (angiotensin II) and XERAVA (eravacycline) in its portfolio that have also been recently launched outside the UK.
GIAPREZA is a vasoconstrictor which has approval for the treatment of refractory hypotension in adults with septic or other distributive shock who remain to be hypotensive in spite of enough volume restitution and application of catecholamines and other existing vasopressor therapies.
On the other hand, XERAVA is a fluorocycline type of antibiotic approved for the treatment of complicated intra-abdominal infections in adults.
As per the terms of the agreement, Clinigen Group will handle the supply and distribution of the licensed products of the German specialty pharma company in the UK.
Sam Herbert — Chief Operating Officer and Head of Products Division of Clinigen Group said: “We are pleased to be partnering with PAION for their first commercial launch in the UK and to be able to offer Byfavo to healthcare providers across the UK through our lifecycle platform. We look forward to building a long and successful relationship with PAION that can help patients in the UK get access to the healthcare they need.”